沙利度胺联合化疗对晚期卵巢癌患者血清VEGF、bFGF、TNF-α及CA125水平影响的研究  

Effects on VEGF,bFGF,TNF-α and CA125 in advanced ovarian cancer patients treated with Thalidomide combined with chemotherapy

作　　者：杨鑫磊[1] 刘文[1] 宿星[1] 李娜[2] 王于理[2] 巩平[2] 

机构地区：[1]石河子大学医学院,新疆石河子832000 [2]石河子大学第一附属医院肿瘤内科,新疆石河子832000

出　　处：《现代肿瘤医学》2012年第12期2603-2605,共3页Journal of Modern Oncology

基　　金：新疆石河子大学医学院第一附属医院院级科研项目(编号:YL2009020)

摘　　要：目的:研究沙利度胺(thalidomide,Thd;酞咪哌啶酮)联合化疗对晚期卵巢癌患者治疗前后血清中血管内皮生长因子(vascular endothelial growth factor,VEGF)、碱性成纤维生长因子(basic fibroblast growth factor,bFGF)、肿瘤坏死因子(tumor necrosis factor,TNF-α)及糖类抗原125(human carbonhydrate antigen 125,CA125)水平的影响。方法:2010年7月至2011年10月,石河子大学医学院第一附属医院收治的晚期卵巢癌患者30例,随机分为沙利度胺组(n=15)与对照组(n=15)。沙利度胺组接受"紫杉醇+卡铂+沙利度胺"联合治疗,对照组除无沙利度胺外,用药方案同沙利度胺组。采集各组患者化疗前和化疗两周期后静脉血,采用酶联免疫吸附(enzyme linked immunosorbent assay,ELISA)检测沙利度胺组和对照组患者血清中VEGF、bF-GF、TNF-α及CA125的表达水平并评价临床疗效。结果:在两组毒副反应无统计学差异的前提下,沙利度胺组有效率为66.67%,临床获益率为93.33%;对照组有效率为33.33%,临床获益率为86.67%。沙利度胺组总有效率及获益率均高于对照组,两组间有效率差异有统计学意义(P<0.05),临床获益率差异无统计学意义(P>0.05)。治疗前后两组患者血清中VEGF、bFGF、TNF-α及CA125的含量变化差异有统计学意义(P<0.05),且沙利度胺组较对照组可更好的降低患者血清VEGF、bFGF、TNF-α的含量,差异有统计学意义(P<0.05),但两组CA125降低幅度差异无统计学意义(P>0.05)。结论:沙利度胺联合"紫杉醇+卡铂"方案应用于晚期卵巢癌患者,在不增加药物毒副反应的前提下,有提升近期疗效的趋势。Objective：To investigate the changes of vascular endothelial growth factor（VEGF）,tumor necrosis factor（TNF-α）,basic fibroblast growth factor（bFGF） and human carbonhydrate antigen 125（CA125） before and after the new chemotherapy regimen：thalidomide plus the chemotherapy regimen of paclitaxel ＋ carboplatin was executed on patients of advanced ovarian cancer.Method：Thirty patients of advanced ovarian cancer treated in First Affilireatated Hospital of Shihezi University School of Medicine were randomly divided into Thalidomide group（n=15） and the control group（n=15）.The Thalidomide group was treated in the new therapy of paclitaxel ＋ carboplatin ＋ thalidomide while the control group paclitaxel ＋ carboplatin.To collect the venous blood before and after two cycles of chemotherapy.Then to detect the detection of level index include VEGF,TNF-α,bFGF and CA125 with ELISA（enzyme linked immunosorbent assay）.Results：Toxicity in the two groups had no significant difference in the premise of thalidomide group was 66.67%,clinical benefit rate of 93.33%;the control group was 33.33%,clinical benefit rate of 86.67%.Thalidomide group was with the total efficiency and higher benefit rates,the efficiency difference between the two groups was statistically significant（P0.05）,clinical benefit rate was no significant difference（P0.05）.Two groups of patients before and after treatment serum,VEGF,bFGF,TNF-α and CA125 levels change significantly（P0.05）,and the thalidomide group than in the control group may be better to reduce serum VEGF,bFGF,TNF-α levels,the difference was statistically significant（P0.05）,but CA125 was no significant difference（P0.05）.Conclusion：This new therapy：thalidomide plus the chemotherapy regimen of paclitaxel ＋ carboplatin can increase curative effect to patients with advanced ovarian cancer and does not increase the drug toxicity.

关 键 词：沙利度胺 晚期卵巢癌 化疗 

分 类 号：R737.31[医药卫生—肿瘤]